Propanc Biopharma to acquire $100 million in Ethereum to diversify its assets

Biopharmaceutical company Propanc Biopharma (Nasdaq: PPCB) announced plans to acquire $100 million in Ethereum over the next 12 months. Ethereum boasts smart contract and DApp support, greater energy efficiency than Bitcoin, and advantages in asset tokenization, including liquidity and global accessibility. The company will primarily use the funds to hold the Ethereum, with a portion allocated for drug development and IP acquisition.